LONG-TERM SAFETY OF SODIUM OXYBATE IN PAEDIATRIC NARCOLEPSY WITH CATAPLEXY: OPEN-LABEL CONTINUATION AFTER 1 YEAR OF TREATMENT

被引：0
|
作者：
Strunc, M. J. [1 ]
Mignot, E. [2 ]
Wang, Y. G. [3 ]
Black, J. [2 ,3 ]
Chakravarthy, D. [3 ]
Parvataneni, R. [3 ]
Plazzi, G. [4 ]
机构：
[1] Childrens Hosp Kings Daughters, Ctr Pediat Sleep Med, Norfolk, VA USA
[2] Stanford Ctr Sleep Sci & Med, Stanford, CA USA
[3] Jazz Pharmaceut Inc, Palo Alto, CA USA
[4] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy
来源：
SLEEP MEDICINE | 2019年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S412 / S412
页数：1
相关论文
共 50 条
  • [31] Open-label long-term use of divalproex sodium in headache
    Diamond, S
    Freitag, FG
    Diamond, ML
    Urban, GJ
    Pepper, BJ
    Bhambhavani, D
    HEADACHE QUARTERLY-CURRENT TREATMENT AND RESEARCH, 1997, 8 (01): : 42 - 44
  • [32] Efficacy and safety of sodium oxybate treatment in adults with narcolepsy and cataplexy: a systematic review and meta-analysis
    Amin, Ahmed Mostafa
    Hassan, Ahmed
    Khlidj, Yehya
    Mansour, Ahmed
    Esawy, Ahmed
    Mohamed, Rashad G.
    Mansour, Anas
    Abbas, Abdallah
    SLEEP AND BREATHING, 2025, 29 (01)
  • [33] Long-term safety of deutetrabenazine for the treatment of tardive dyskinesia: Results from an open-label, long-term study
    Anderson, K.
    Stamler, D.
    Davis, M.
    Factor, S.
    Hauser, R.
    Isojarvi, J.
    Jarskog, L.
    Jimenez-Shahed, J.
    Kumar, R.
    Ochudlo, S.
    Ondo, W.
    Fernandez, H.
    MOVEMENT DISORDERS, 2017, 32
  • [34] LONG-TERM SAFETY AND EFFICACY OF EXTENDED-RELEASE ONCE-NIGHTLY SODIUM OXYBATE FOR NARCOLEPSY
    Corser, B. C.
    Morse, A. M.
    Stern, T.
    Ajayi, A. O.
    Kushida, C. A.
    Gudeman, J.
    SLEEP MEDICINE, 2024, 115 : 220 - 220
  • [35] Long-term olanzapine therapy in the treatment of bipolar I disorder: An open-label continuation phase study
    Sanger, TM
    Grundy, SL
    Gibson, PJ
    Namjoshi, MA
    Greaney, MG
    Tohen, MF
    JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (04) : 273 - 281
  • [36] Long-Term Open-Label Safety Study of Rizatriptan Acute Treatment in Pediatric Migraineurs
    Hewitt, David J.
    Pearlman, Eric
    Hamalainen, Mirja
    Lewis, Donald
    Connor, Kathryn M.
    Michelson, David
    Ceesay, Paulette
    Assaid, Christopher
    Bachman, Robert
    Mozley, Lyn Harper
    Dupre, Nicole
    Strickler, Nancy
    Mahoney, Erin
    Lines, Christopher
    Ho, Tony W.
    HEADACHE, 2013, 53 (01): : 104 - 117
  • [37] A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine
    Croop, Robert
    Berman, Gary
    Kudrow, David
    Mullin, Kathleen
    Thiry, Alexandra
    Lovegren, Meghan
    L'Italien, Gilbert
    Lipton, Richard B.
    CEPHALALGIA, 2024, 44 (04)
  • [38] Long-term treatment with zonisamide: Results of a 2 year open-label extension study
    Wroe, S.
    Duncan, R.
    EPILEPSIA, 2006, 47 : 138 - 138
  • [39] Sodium Oxybate in the Treatment of Binge Eating Disorder: An Open-Label, Prospective Study
    McElroy, Susan L.
    Guerdjikova, Anna I.
    Winstanley, Erin L.
    O'Melia, Anne M.
    Mori, Nicole
    Keck, Paul E., Jr.
    Hudson, James I.
    INTERNATIONAL JOURNAL OF EATING DISORDERS, 2011, 44 (03) : 262 - 268
  • [40] Safety of long-term use of linezolid: results of an open-label study
    Vazquez, Jose A.
    Arnold, Anthony C.
    Swanson, Robert N.
    Biswas, Pinaki
    Bassetti, Matteo
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 1347 - 1354
12345